Gene therapy for ovarian cancer.

Détails

ID Serval
serval:BIB_3910F18935B6
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Gene therapy for ovarian cancer.
Périodique
Oncology
Auteur(s)
Coukos G., Rubin S.C.
ISSN
0890-9091 (Print)
ISSN-L
0890-9091
Statut éditorial
Publié
Date de publication
2001
Volume
15
Numéro
9
Pages
1197-1204, 1207; discussion 1207-1208
Langue
anglais
Notes
Publication types: Journal Article ; ReviewPublication Status: ppublish
Résumé
Advances in molecular virology and biotechnology have led to the engineering of vectors that can efficiently transfer genes to target cells. Gene therapy strategies were developed along two lines: Cytotoxic approaches involve the transfer of genes that encode enzymes, which convert inactive prodrugs into cytotoxic drugs. Corrective gene therapy approaches aim to repair specific molecular alterations in signal transduction mechanisms that control the cell cycle or induce apoptosis. Clinical evidence suggests that gene therapies are best suited for patients with minimal residual disease. Multimodality approaches with conventional strategies and novel therapeutic tools in various combinations will most likely prove advantageous, compared to single-modality treatments. However, clinical trials will need to test these hypotheses.
Mots-clé
Female, Genes, BRCA1, Genes, p16, Genes, p53, Genetic Therapy/methods, Genetic Vectors/therapeutic use, Humans, Ovarian Neoplasms/genetics, Ovarian Neoplasms/therapy
Pubmed
Création de la notice
14/10/2014 12:43
Dernière modification de la notice
20/08/2019 14:28
Données d'usage